TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06391827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-7503 Single dose
Description: Oral administration for once; Dose strength is different for each cohort(Cohort 1, 2, 3, 4 and 5).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-7503 Multiple dose
Description: Oral administration once daily for 7 days; Dose strength or target volunteer is different for each cohort(Cohort 1,2,3, and 4)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Single dose
Description: Oral administraion for once.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Multiple dose
Description: Oral administration once daily for 7 days
Study: NCT05673694

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EG017
Description: According to the dosage group of the program, once a day.
Study: NCT05356559

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Intervention
Description: 12.5g (twice daily) Blue Whiting Protein Hydrolysates daily for 8 weeks
Study: NCT06393673

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-10384 tablet Dose 1
Description: Administered orally QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-10384 tablet Dose 2
Description: Administered orally QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-10384-matched placebo tablets
Description: Administered orally QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-10384-matched placebo tablets
Description: Administered orally QD

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HS-10384-matched placebo tablets
Description: Administered orally QD
Study: NCT05672394

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Continuous Serratus anterior plane block
Description: in lateral position a linear transducer (10-12MHz, M-Turbo) will be used, The 5th rib is identified in the mid-axillary line. The following muscles are overlying the rib latissimusdorsi ,teres major, and serratus muscle.The needle (22G, 50-mm Tuohy needle) is introduced in-plane targeting the plane superficial to serratus muscle. local anesthetic is injected then a catheter is threaded and . Ultrasound-guided SAPB was done using a serratus anterior catheter Group DL (n=20) received a bolus of 30 mL of 0.25% bupivacaine followed by a continuous infusion of 0.125% bupivacaine at a rate of 7-12 ml/hr according to patient response upon ICU arrival after the stabilization of the clinical status. The infusion was continued until the end of the 1st 24 hours postoperatively .

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic Epidural
Description: A thoracic epidural catheter was done to the patient while sitting. Tuohy needles are used. Epidural space can be identified by loss of resistance. Injection begins with a negative aspiration and a test dose (3 ccs of 1.5% lidocaine with 1:200,000 epinephrine) .A Continuous epidural technique through the placement of a catheter 3-5 cm beyond the needle is applied. Injection in 5ml increments of 0.25% bupivacaine is used until the block of the required segments achieved ( 10 to 15ml). sensory testing is via pinprick and cold test to detect sympathetic block . Throughout the technique hourly injection of 5 ml 0.25% bupivacaine for maintenance.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: bupivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: bupivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine with epinephrine
Description: 3 ccs of 1.5% lidocaine with 1:200,000 epinephrine
Study: NCT04790903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Participants will receive Doxorubicin at a dose of 50 mg/m\^2 by IV infusion or bolus on Day 1 of Cycles 1-6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Participants will receive Doxorubicin at a dose of 50 mg/m\^2 by IV infusion or bolus on Day 1 of Cycles 1-6.
Study: NCT05356559

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Isocalorific Maltodextrin Citrus Flavoured Powder for 8 weeks
Study: NCT04790903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Participants will receive Prednisone orally (PO) at a dose of 100 mg/day on Days 1-5 of Cycles 1-6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Participants will receive Prednisone orally (PO) at a dose of 100 mg/day on Days 1-5 of Cycles 1-6.
Study: NCT04784091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TP-03
Description: TP-03, lotilaner ophthalmic solution, 0.25%, administered twice a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TP-03 Vehicle
Description: Vehicle of TP-03 ophthalmic solution, administered twice a day
Study: NCT05736432

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Blueberries
Description: Experimental condition

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Blueberries
Description: Experimental condition

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo condition

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo condition
Study: NCT06109402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2450
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2450
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Specified dose on specified days

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Surgery for II-IIIB (N2) non-small cell lung cancer

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Surgery for II-IIIB (N2) non-small cell lung cancer
Study: NCT06537609

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: De-escalation VS No De-escalation
Description: No de-escalation group: continue to receive the same antibiotic that was started initially (as long as it is confirmed to be effective based on the blood culture sensitivity result). De-escalation is only allowed within 7 days if patient is being discharged from hospital.~De-escalation group: switched to narrower spectrum antibiotic (based on spectrum scale specified in protocol).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oral beta-lactams VS non beta-lactams
Description: Beta-lactam antibiotic: This can be, but not limited to, amoxicillin, amoxicillin-clavulanate, cephalexin, cefadroxil, or cefixime.~Non beta-lactam antibiotic: This can be ciprofloxacin, moxifloxacin, levofloxacin or trimethoprim-sulfamethoxazole.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Central vascular catheter retention VS Central vascular catheter replacement
Description: Central vascular catheter replacement: the catheter will be changed by the treating team as soon as possible and within a maximum of 72 hours from blood culture finalization~Central vascular catheter retention: the catheter will not be changed and will be retained until it is non functional or no longer needed.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cephalosporin VS Carbapenem for low risk AmpC organisms
Description: Cephalosporin (ceftriaxone) at standard doses~Carbapenem (Meropenem or Ertapenem) at standard doses

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine follow-up blood culture VS No routine follow-up blood culture
Description: Routine follow-up blood culture: routine repeat blood collection 4 days from the index blood collection with positive bacteria.~No follow-up blood culture: no routine repeat blood collection 4 days from the index blood collection with positive bacteria
Study: NCT05791097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ociperlimab
Description: Ociperlimab is a monoclonal antibody formulated for intravenous infusion. 900 mg of ociperlimab will be administered on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo infusions will consist of a sterile, normal saline solution. Placebo will be administered on Day 1 of each 21-day cycle
Study: NCT05306106

Intervention type: OTHER
Group type: OTHER
Intervention: elderflower madeleine
Description: The products evaluated are pastries from the Mademoiselle Desserts range. The amounts consumed will be calculated for each of the pastries so that 50 g of carbohydrate is ingested per intake. Subjects may consume 200 mL of water after ingesting the pastries. During visits V2 to V4 and V6 to V8, the subject will consume successively the pastries which will have been assigned to him randomly and according to the randomization list.~During the visit : A venous catheter will be placed by a medical biology technician and a blood sample will be taken immediately after placement: this is the first sample at T = 0 min. Then, the subject will have a maximum of 10 minutes to consume 294.1 g of elderflower madeleine (contained 50 g of glucose). The technician will then take blood samples at T = 15, T = 30, T = 45, T = 60, T = 90 and T = 120 minutes.
Study: NCT06571461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Irinotecan
Description: Liposomal Irinotecan：i.v. infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin;：i.v. infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: S-1: Oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine: i.v. infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine: Oral
Study: NCT04840745

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-841 A-1 3.75mg
Description: Single injection, subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-841 A-1 1.88mg
Description: Single injection, subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-841 D 2.92mg
Description: Single injection, subcutaneous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leuplin Inj. 3.75 mg
Description: Single injection, subcutaneous injection
Study: NCT04928352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Hydrochloride
Description: Preoperative Nebulized Bupivacaine 0.50% 0.25 mg.kg-1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Hydrochloride
Description: Preoperative Nebulized Bupivacaine 0.50% 0.50 mg.kg-1

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% saline
Description: Preoperative nebulized same volume of saline placebo
Study: NCT05234619

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group one ( lidocaine or control LE ) Early deflation
Description: This will be conducted on 20 trauma patients group one who will be present for both elective and emergency Hand and Forearm surgery After establishing noninvasive arterial blood pressure, ECG, peripheral oxygen saturation monitoring, two venous cannulae will be inserted: one in a vein in the dorsum of operative hand and the other in the opposite hand for crystalloid infusion.~The opposite arm will be elevated for 2 minutes, and using an Esmarch bandage, the venous capacitance of the arm will be emptied. Then, a double-pneumatic tourniquet will be applied. The proximal tourniquet will be inflated to a pressure of 250 mmHg and circulatory isolation of the arm will be confirmed by inspection, lack of radial pulse and failure of pulse oximetry tracing of ipsilateral index finger then Esmarch bandage will be released then induction of lidocaine for intravenous regional anesthesia ( Bier block ) and Early deflation of distal tourniquet occurs after 20 minutes of IVRA induction
Study: NCT05191498

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: QuiremSpheres®
Description: Intratumoral injection of QuiremSpheres® up to a dose of 150 Gy.
Study: NCT06126562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanifibranor
Description: Lanifibranor is a pan-peroxisome proliferator-activated receptor (PPAR) agonist.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanifibranor
Description: Lanifibranor is a pan-peroxisome proliferator-activated receptor (PPAR) agonist.
Study: NCT06535581

Intervention type: PROCEDURE
Intervention: surgery patient
Description: patients with hypertension (group 2) and without (group 1) hypertension. The predictive ability of postoperative pain as a tool for measuring and assessing pain was examined by analysing the relative change in the Perfuston index.

Intervention type: PROCEDURE
Intervention: surgery patient
Description: patients with hypertension (group 2) and without (group 1) hypertension. The predictive ability of postoperative pain as a tool for measuring and assessing pain was examined by analysing the relative change in the Perfuston index.
Study: NCT04800185

Intervention type: DRUG
Group type: OTHER
Intervention: Crisaborole 2% Top Oint
Description: To analyze the skin microbiome of patients with atopic dermatitis before, during, and after treatment with crisaborole 2% ointment

Intervention type: GENETIC
Group type: OTHER
Intervention: Skin Microbiome Swabs
Description: At the baseline visit the investigator will identify sites for swabbing the skin including one affected distinct crisaborole-treated AD lesion, and one untreated AD lesion. The lesions will both be sampled at baseline, 14 days into treatment, 28 days into treatment, 3 months into treatment, and 4 weeks after treatment completion. Photographs of each lesion will be taken for reference. Skin swabs will be obtained in a sterile fashion using a BD Culture SwabsTM EZ Collection and Transport System (or equivalent) and soaked with sterilized 0.15 M NaCl and 0.1% Tween-20. The samples will be frozen at -80 C, kept at this temperature, and stored until analysis may be completed.
Study: NCT06416488

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIIT intervention
Description: Modified HIIT in Tabata mode, which followed a pattern of 3 sets, with each set consisting of 4 repetitions of 20 seconds of high-intensity exercise followed by 10 seconds of rest, at least 3 times per week.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General health education
Description: General instructions on promoting healthy diet and exercise, primarily by sending offline and online promotion materials to participants.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: General health education
Description: General instructions on promoting healthy diet and exercise, primarily by sending offline and online promotion materials to participants.
Study: NCT04930029

Intervention type: OTHER
Intervention: Ten year evaluation
Description: Clinical, biological and endoscopic evaluation

Intervention type: OTHER
Intervention: Ten year evaluation
Description: Clinical, biological and endoscopic evaluation
Study: NCT04888000

Intervention type: OTHER
Group type: OTHER
Intervention: Educational Intervention
Description: Professional development program provided to small groups of health care professionals in three different sessions over a period of one month with additional independent individual work to be completed between sessions.
Study: NCT06363916

Intervention type: DEVICE
Intervention: Insulin Management System in Manual mode of operation
Description: MEDTRUM A8 TouchCare® Insulin Management system which includes:~* Patch pump: Pump base integrated with Hybrid Close Loop (HCL) algorithm not activated~* Reservoir Patches~* Continuous glucose monitoring (CGM): Glucose Sensor + Transmitter~* Personal Diabetes Manager (PDM) and/or EasyPatch® App~* EasyFollow® App, EasyView® website System is in conformity with EC marking n° HD 601 357 110001- TUV Rheinland dated February 19th of year 2019 and completed by system DoC 881160 dated June 30th of year 2020.~EasyPatch mobile application is in conformity with EC marking n°709972 - BSI - dated March 6th 2020
Study: NCT05234619

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group two ( lidocaine , ketorolac LKE ) Early deflation
Description: As the first intervention this will be conducted on group two but ketorolac will be combined with lidocaine in intravenous regional anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group three ( lidocaine or control LL ) Late deflation
Description: As the first intervention this will be conducted on group three but late deflation of distal tourniquet in intravenous regional anesthesia after 40 minutes of induction of lidocaine for IVRA .
Study: NCT06363916

Intervention type: DEVICE
Intervention: Insulin Management System in Automatic mode of operation
Description: MEDTRUM A8 TouchCare® Insulin Management system which includes:~* Patch pump: Pump base integrated with Hybrid Close Loop (HCL) algorithm activated~* Reservoir Patches~* Continuous glucose monitoring (CGM): Glucose Sensor + Transmitter~* Personal Diabetes Manager (PDM) and/or EasyPatch® App~* EasyFollow® App, EasyView® website System is in conformity with EC marking n° HD 601 357 110001- TUV Rheinland dated February 19th of year 2019 and completed by system DoC 881160 dated June 30th of year 2020.~EasyPatch mobile application is in conformity with EC marking n°709972 - BSI - dated March 6th 2020
Study: NCT05002322

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Systems Analysis and Improvement Approach
Description: Intensive phase: district MOH supervisors receive a one-week training on SAIA-HTN. The nine-month intervention wave will be mentored by INS study personnel who will accompany and support district MOH supervisors as they implement at the facility level. Over the first week of each iterative cycle, facility teams populate and interpret the HCAT, develop process maps, define one to two micro-interventions and indicators to monitor these modifications. Facility teams receive two mentorship visits by district supervisors and study personnel for the first month, followed by monthly visits throughout intensive implementation.~Sustainment phase (depending on implementation wave allocation): district supervisors will independently lead implementation, with financial support for travel to clinics and to hold meetings, but without intensive support from study personnel.
Study: NCT05234619

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group four ( lidocaine , ketorolac LKL ) Late deflation
Description: As the first intervention this will be conducted on group four but late deflation of distal tourniquet in intravenous regional anesthesia after 40 minutes of induction of lidocaine and ketorolac for IVRA .
Study: NCT04528563

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac Tromethamine 10 MG/ML
Description: Non-Steroidal-Anti-Inflammatory given intravenously.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine Sulfate 10Mg/1mL Injection
Description: Opioid commonly used for acute abdominal pain given intravenously.
Study: NCT05580900

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Livestream Modality (treatment)
Description: For this evaluation, the livestream modality is considered the treatment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Live Modality (control)
Description: For this evaluation, the live or in-person modality is considered the control group.
Study: NCT06666517

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: surgery (any volume) and / or pharmaceuticals treatment initiated or planned or only dynamic observation, in accordance with current clinical guidelines
Description: Routine surgery after neoadjuvant chemotherapy for breast cancer according to current guidelines.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Immunohistochemistry Analysis
Description: Determination of breast cancer subtypes through immunohistochemical analysis, and selection of Luminal B, HER2-positive, and triple-negative groups.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Second Biopsy
Description: Taking biopsies from the center of the tumor and the peritumoral stroma of the same mass during marking of the mass before neoadjuvant chemotherapy
Study: NCT06356038

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intra-operative phrenic nerve infiltration
Description: patients received the intra-operative infiltration of phrenic nerve by the surgeon who injected 10 ml of Ropivacaine 0.75% (the same procedure routinely adopted in our clinical practice for local analgesia at the level of the intercostal space) in the peri-neurotic pericardial fat, near the diaphragm. Infiltration is made with a deflated lung, after pulmonary resection and chest tube insertion.
Study: NCT04655365

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide capsule
Description: 160 mg po id
Study: NCT06573710

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sonic activator
Description: Polyamide EDDY tips 28mm long is inserted in the canal 2mm short of the working length operated at 6,000 Hz. Activation is done for three cycles each for 20sec. The tip is moved vertically in up and down motion, 1ml is used for each activation cycle followed by 2ml 17% EDTA20
Study: NCT05061459

Intervention type: GENETIC
Intervention: circANKRD36 as a new biomarker
Description: expression levels of circANKRD36 in the development and progression of DN
Study: NCT06573710

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LASER activation
Description: Diode laser 980nm is used to activate the irrigant using fiber optic tip of (200micrometer) and power of 1.5w continuous mode. The tip is placed 2 mm shorter than the working length. Laser irradiation is done for each canal for 20 secs repeated over three cycles for total time of 60 secs and 10 secs pauses between each cycle

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasonic activation
Description: ED60tip is used with ultrasonic device operated on mode E and inserted in the canal 2mm short of the working. Activation is done for three cycles each for 20 sec. The tip is moved vertically in up and down motion,1ml is used for each activation cycle followed by 2ml 17% EDTA

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: passive irrigation with Endodontic needle
Description: Each canal is irrigated with side vented endodontic needle 30G Placed 2mm short of the working length with total time of 60 secs followed by 2ml 17% EDTA